Separation Or Purification (e.g., Resolving Isomeric Mixtures, Etc.) Patents (Class 536/27.12)
-
Patent number: 8969545Abstract: Alkynyl-derivatized cap analogs, alkynyl-modified capped RNA, 1,4-disubstituted triazole-derivatized capped RNA, methods of preparation, methods of isolation, and uses thereof are provided. The “click” modification facilitates detection and isolation of capped RNAs and the 1,4-disubstituted triazole derivatives formed by the “click” reaction are useful for producing RNA transcripts and encoded protein.Type: GrantFiled: October 18, 2012Date of Patent: March 3, 2015Assignee: Life Technologies CorporationInventors: Anilkumar R. Kore, Shanmugasundaram Muthian, Kyle Gee
-
Publication number: 20140323712Abstract: A new polymorph of 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine (designated as polymorph E), characterized by an X-ray diffraction pattern of X-RPD showing the following reflections at 2 Theta=5.8°, 12.3°, 15.9°, 17.3°, 20.5°, 22.6°, 23.6°, 27.7°, and 29.2°, and further characterized by DSC showing marked endotherm in the range of 258 to 264° C.Type: ApplicationFiled: June 27, 2013Publication date: October 30, 2014Applicant: Farmak, a.s.Inventors: Lubomir KVAPIL, Pavel HRADIL, Martin GREPL, Petr SLEZAR, Barbora DVORAKOVA
-
Patent number: 8686130Abstract: The present invention relates to novel unnatural fluorescent nucleic acid bases, that is, a purine base, a 1-deazapurine base, and a 1,7-deazapurine base each having a functional group which consists of two or more heterocyclic moieties linked together, at the 6-position thereof (the 6-position of purine ring). The present invention also relates to a compound containing the unnatural base, a derivative thereof, and a nucleic acid containing a nucleotide having the unnatural base. The present invention also relates to a method of preparing the nucleic acid. The unnatural base of the present invention has excellent fluorescence characteristics and also has excellent properties as a universal base.Type: GrantFiled: October 6, 2010Date of Patent: April 1, 2014Assignees: Riken, Tagcyx BiotechnologiesInventors: Ichiro Hirao, Michiko Hirao, Shigeyuki Yokoyama, Tsuneo Mitsui
-
Publication number: 20130331561Abstract: The invention is directed to processes for synthesizing bicyclic nucleoside antiviral compounds and for synthesizing the intermediates used in the process. The invention is also directed to novel intermediate compounds useful in the process. The anti-viral compounds are useful in the treatment of herpes zoster (i.e., varicella zoster virus, VZV, shingles) and for the prevention of post herpetic neuralgia (PHN) resulting from this viral infection.Type: ApplicationFiled: October 7, 2011Publication date: December 12, 2013Applicant: SYNERGY PHARMACEUTICALS INC.Inventors: Yanling Wang, Yuan Wang, Xungui He, Chuanjun Liu, Jirang Zhu, Jie Li, Qingzhong Cheng, Mingyong Yuan
-
Publication number: 20120197010Abstract: A method of making cladribine with an increased purity comprising: a) dissolving crude cladribine in a protic solvent in the presence of a base to form a solution comprising dissolved crude cladribine; b) maintaining the solution at an elevated temperature so that the solution is homogeneous until the amount of protected or partially protected nucleoside impurities in the solution is reduced to a pre-determined upper limit; and c) cooling the solution of step b) so that crystals of cladribine are formed and isolated.Type: ApplicationFiled: March 26, 2012Publication date: August 2, 2012Applicant: ScinoPharm (Kunshan) Biochemical Technology Co., Ltd.Inventors: Julian Paul HENSCHKE, Xiaoheng Zhang, Guodong Chu, Lijun Mei, Yung Fa Chen
-
Patent number: 8034924Abstract: Crystals of a purine nucleoside compound, particularly crystals of 2?,3?-dideoxyinosine, which have excellent storage stability and have a concentration of phosphate attached to the crystal of 25 ppm or more, may be produce by: (1) preparing an aqueous solution containing phosphate ion (PO43?) and a purine nucleoside compound; and (2) crystallizing the purine nucleoside compound from the aqueous solution.Type: GrantFiled: July 17, 2009Date of Patent: October 11, 2011Assignee: Ajinomoto Co., Inc.Inventors: Masaki Naito, Yoshitomo Kimura, Hiroya Ueda, Minoru Harada
-
Patent number: 7626017Abstract: Methods for cell lysis and purification of biological materials, involving subjecting a sample to high pressure. Also featured is an apparatus for practicing the methods.Type: GrantFiled: August 16, 2004Date of Patent: December 1, 2009Assignee: Pressure Biosciences, Inc.Inventors: James A. Laugharn, Jr., Robert A. Hess, Feng Tao
-
Publication number: 20090209753Abstract: Aimed at readily and exactly separate 8-hydroxy-2?-deoxyguanosine (8-OHdG) contained in a sample, a column packing material used for separating 8-OHdG, which contains a packing material composed of a material having a straight-chain hydrocarbon group having 6 or more and 30 or less carbon atoms as a functional group, and having a carbon content over the surface of carrier of 18% or less by element ratio, wherein the packing material contains 1 cumulative percent or more and 20 cumulative percent or less, on the particle-count basis, of particles having a circle-equivalent diameter, measured using a flow-type particle image analyzer, of 0.5 ?m or larger and 10 ?m or smaller, is used.Type: ApplicationFiled: February 18, 2009Publication date: August 20, 2009Applicants: TANITA CORPORATION, NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Narushi Ito, Jun Kimura, Masayuki Mizushina, Yohei Inaba, Kenji Yokoyama
-
Patent number: 7247721Abstract: Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.Type: GrantFiled: February 14, 2005Date of Patent: July 24, 2007Inventor: Mark B. Lyles
-
Patent number: 7153840Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.Type: GrantFiled: May 23, 2003Date of Patent: December 26, 2006Assignee: Sicor, Inc.Inventors: Dorla Mirejovsky, Peter Lindsay Macdonald
-
Patent number: 7148207Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.Type: GrantFiled: December 20, 2002Date of Patent: December 12, 2006Assignee: Schering AktiengesellschaftInventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
-
Patent number: 7022835Abstract: The invention concerns a method for binding nucleic acids to a solid phase in which a nucleic acid containing solution is contacted with a solid phase which has hydrophobic and hydrophilic groups on its surface or/and which comprises a hydrophilic, water-containing polymer matrix, in the presence of dehydrating reagents, in particular in the presence of a salt and polyethylene glycol whereby the nucleic acid is bound to the surface.Type: GrantFiled: September 8, 2000Date of Patent: April 4, 2006Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften. E.V.Inventors: Holger Rauth, Richard Reinhardt, Eckard Nordhoff
-
Patent number: 7001724Abstract: The invention provides compositions and methods for releasing and for isolating nucleic acids from biological samples, preferably from whole tissue, using cationic surfactants and proteases. The surfactant-protease combinations, when used with whole tissue, macerate the tissue, lyse individual cells, release nucleic acids, and inactivate nucleases. Kits for isolating nucleic acids from biological samples, particularly from whole tissue, are also provided.Type: GrantFiled: November 28, 2000Date of Patent: February 21, 2006Assignee: Applera CorporationInventor: I. Lawrence Greenfield
-
Patent number: 6855817Abstract: Surfaces containing high purity silica (silicon dioxide) exhibit high loading potential for nucleic acids. Formulations containing nucleic acids and materials which mask the electrostatic interactions between the nucleic acids and surfaces are disclosed. By masking the phosphate charges of the nucleic acids, undesired interactions may be minimized or eliminated, thereby allowing the covalent bonding of the nucleic acids to the surface to proceed. The use of such formulations additionally minimizes nonspecific binding of the nucleic acids to the surface. Examples of materials to be included in such formulations include cations, xanthines, hexoses, purines, arginine, lysine, polyarginine, polylysine, and quaternary ammonium salts.Type: GrantFiled: July 20, 2001Date of Patent: February 15, 2005Inventor: Mark B. Lyles
-
Patent number: 6762027Abstract: The invention relates to compositions and methods for isolating nucleic acids from biological samples, including whole tissue. The invention also provides kits for isolating nucleic acids from biological samples.Type: GrantFiled: November 28, 2001Date of Patent: July 13, 2004Assignee: Applera CorporationInventors: Lawrence Greenfield, Luz Montesclaros
-
Patent number: 6579976Abstract: There can be provided an excellent industrial process for producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids or in derivatives thereof by allowing O-thiocarbonyl derivatives of sugar-moiety hydroxyl groups or allowing halogenated derivatives in the sugar-moiety, in the nucleic acids or in derivatives thereof to react with any one of hypophosphorous acids (including salts thereof) and phosphites (esters) which are inexpensive, non-toxic and safely usable as radical reducing agents in industrial scale, in the presence of a radical reaction initiator. The process of the present invention is an industrially useful and highly safe process for reducing sugar-moiety hydroxyl groups and halogen atoms in nucleic acids or derivatives thereof (including nucleic acid-related compounds) at low costs.Type: GrantFiled: October 26, 1999Date of Patent: June 17, 2003Assignee: Ajinomoto Co., Inc.Inventors: Satoshi Takamatsu, Satoshi Katayama, Naoko Hirose, Kunisuke Izawa
-
Patent number: 6559299Abstract: The present invention relates to a novel process to make indolocarbazole glycosides in high purity which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.Type: GrantFiled: March 21, 2002Date of Patent: May 6, 2003Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.Inventors: Steven Weissman, David Tschaen, Asayuki Kamatani, Shouichi Hiraga, Masashi Kawasaki, Takehiko Iida
-
Patent number: 6555677Abstract: The present invention relates to a novel glycosidation process to make intermediates useful in the preparation of indolopyrrolocarbazole derivatives which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.Type: GrantFiled: October 22, 2001Date of Patent: April 29, 2003Assignee: Merck & Co., Inc.Inventors: Daniel E. Petrillo, Steven A. Weissman, Shouichi Hiraga, Nobuya Satake, Kai Rossen
-
Patent number: 6414137Abstract: A process for the purification of nucleosides, and more particularly to a selective solvent extraction method for purifying protected nucleosides. In the purification process, solid particles of protected nucleosides are selectively washed to remove undesirable polar and/or non-polar impurities, while leaving the solid particles substantially undissolved.Type: GrantFiled: November 15, 1999Date of Patent: July 2, 2002Assignee: AlliedSignal Inc.Inventors: Raymond J. Swedo, Mathias P. Koljack, Romulus Gaita, Stephen Frederick Yates, Charles Wu
-
Publication number: 20020058635Abstract: Novel purine L-nucleoside compounds are disclosed, in which both the purine rings and the sugar are either modified, functionalized, or both. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Th1 and Th2.Type: ApplicationFiled: October 30, 2001Publication date: May 16, 2002Inventor: Devron R. Averett